| Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD NA Kennedy, S Lin, JR Goodhand, N Chanchlani, B Hamilton, ... Gut 70 (10), 1884-1893, 2021 | 257 | 2021 |
| Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab NA Kennedy, JR Goodhand, C Bewshea, R Nice, D Chee, S Lin, ... Gut 70 (5), 865-875, 2021 | 175 | 2021 |
| Complementary and alternative medicines used by patients with inflammatory bowel diseases AS Cheifetz, R Gianotti, R Luber, PR Gibson Gastroenterology 152 (2), 415-429. e15, 2017 | 162 | 2017 |
| Turmeric induced liver injury: a report of two cases RP Luber, C Rentsch, S Lontos, JD Pope, AK Aung, HG Schneider, ... Case reports in Hepatology 2019, 2019 | 48 | 2019 |
| Low mass blood peptides discriminative of inflammatory bowel disease (IBD) severity: a quantitative proteomic perspective VC Wasinger, Y Yau, X Duo, M Zeng, B Campbell, S Shin, R Luber, ... Molecular & Cellular Proteomics 15 (1), 256-265, 2016 | 39 | 2016 |
| Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study S Sebastian, GJ Walker, NA Kennedy, TE Conley, KV Patel, ... The Lancet Gastroenterology & Hepatology 6 (4), 271-281, 2021 | 29 | 2021 |
| Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA. 1 and BA. 4/5 variants in patients with inflammatory bowel disease treated with infliximab and … Z Liu, K Le, X Zhou, JL Alexander, S Lin, C Bewshea, N Chanchlani, ... The Lancet Gastroenterology & Hepatology 8 (2), 145-156, 2023 | 24 | 2023 |
| Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease A Vasudevan, N Parthasarathy, D Con, S Nicolaides, R Apostolov, ... Alimentary Pharmacology & Therapeutics 52 (7), 1174-1184, 2020 | 21 | 2020 |
| Can we predict the toxicity and response to thiopurines in inflammatory bowel diseases? RP Luber, S Honap, G Cunningham, PM Irving Frontiers in Medicine 6, 279, 2019 | 21 | 2019 |
| Depression, anxiety, and stress among inflammatory bowel disease patients during COVID‐19: A UK cohort study RP Luber, A Duff, P Pavlidis, S Honap, S Meade, S Ray, SH Anderson, ... JGH Open 6 (1), 76-84, 2022 | 18 | 2022 |
| The effects of COVID‐19 on IBD prescribing and service provision in a UK tertiary centre E Sharma, S Meade, F D’errico, P Pavlidis, R Luber, S Zeki, K Hill, A Duff, ... GastroHep 2 (6), 318-326, 2020 | 17 | 2020 |
| 6-Thioguanine nucleotide levels are associated with mucosal healing in patients with Crohn’s disease R Mao, J Guo, R Luber, BL Chen, Y He, ZR Zeng, S Ben-Horin, ... Inflammatory Bowel Diseases 24 (12), 2621-2627, 2018 | 17 | 2018 |
| An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch RP Luber, R O'Neill, S Singh, E Sharma, G Cunningham, S Honap, ... Alimentary Pharmacology & Therapeutics 54 (5), 678-688, 2021 | 13 | 2021 |
| A retrospective cohort study: pre‐operative oral enteral nutritional optimisation for Crohnʼs disease in a UK tertiary IBD centre S Meade, KV Patel, RP Luber, D O'Hanlon, A Caracostea, P Pavlidis, ... Alimentary Pharmacology & Therapeutics 56 (4), 646-663, 2022 | 12 | 2022 |
| Thiopurines and their optimization during infliximab induction and maintenance: a retrospective study in Crohn's disease RP Luber, L Dawson, S Munari, VC Kariyawasam, C Martin, PR Gibson, ... Journal of Gastroenterology and Hepatology 36 (4), 990-998, 2021 | 8 | 2021 |
| Anogenital Crohn’s disease and granulomatosis: a systematic review of epidemiology, clinical manifestations, and treatment S Honap, S Meade, A Spencer, P Pavlidis, RP Luber, E Calonje, ... Journal of Crohn's and Colitis 16 (5), 822-834, 2022 | 6 | 2022 |
| Positioning intestinal ultrasound in a UK tertiary centre: significant estimated clinical role and cost savings RP Luber, B Petri, S Meade, S Honap, S Zeki, KB Gecse, N Griffin, ... Frontline gastroenterology 14 (1), 52-58, 2023 | 5 | 2023 |
| Development of a simple, serum biomarker-based model predictive of the need for early biologic therapy in Crohn’s disease D Con, N Parthasarathy, M Bishara, RP Luber, N Joshi, A Wan, ... Journal of Crohn's and Colitis 15 (4), 583-593, 2021 | 5 | 2021 |
| Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID‐19 pandemic: the PREPARE‐IBD multicentre cohort study A Saifuddin, AJ Kent, SJ Mehta, LC Hicks, HA Gonzalez, JP Segal, ... Alimentary Pharmacology & Therapeutics 56 (10), 1460-1474, 2022 | 4 | 2022 |
| Recurrent Campylobacter jejuni Infection in an Immunodeficient Patient Treated with Repeated Faecal Microbiota Transplant (FMT)—A Case Report B Merrick, AG Tamilarasan, R Luber, PFK Yong, K Cheent, PM Irving, ... Infectious Disease Reports 14 (1), 56-62, 2022 | 4 | 2022 |
